Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

A multicentre study of 244 pregnancies in undifferentiated connective tissue disease: maternal/fetal outcomes and disease evolution

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Hydroxychloroquine in patients with rheumatic diseases during the COVID-19 pandemic: a letter to clinicians

    Research output: Contribution to journalLetterResearchpeer-review

  2. Hydroxychloroquine reduces IL-6 and pro-thrombotic status

    Research output: Contribution to journalLetterResearchpeer-review

  • Massimo Radin
  • Karen Schreiber
  • Irene Cecchi
  • Alessandra Bortoluzzi
  • Francesca Crisafulli
  • Cristiano M de Freitas
  • Beatrice Bacco
  • Elena Rubini
  • Silvia G Foddai
  • Melissa Padovan
  • Silvia Gallo Cassarino
  • Franco Franceschini
  • Danieli Andrade
  • Chiara Benedetto
  • Marcello Govoni
  • Tiziana Bertero
  • Luca Marozio
  • Dario Roccatello
  • Laura Andreoli
  • Savino Sciascia
View graph of relations

OBJECTIVES: To investigate fetal/perinatal and maternal outcomes from a large multicentre cohort of women diagnosed with UCTD.

METHODS: This multicentre retrospective cohort study describes the outcomes of 224 pregnancies in 133 consecutive women with a diagnosis of UCTD, positive for ANA and aged <45 years old at study inclusion.

RESULTS: Of the 224 pregnancies analysed, 177 (79%) resulted in live births, 45 (20.1%) in miscarriages (defined as pregnancy loss before 12 weeks' gestation), 2 (0.9%) in stillbirths (pregnancy loss after 20 weeks' gestation) and 6 (2.7%) cases showed intrauterine growth restriction. Miscarriages and stillbirths were strongly associated with the presence of aPL and ENA antibodies (P < 0.05). Maternal pregnancy complications were as follows: 5 (2.2%) cases developed pre-eclampsia, 11 (4.9%) cases gestational hypertension and 12 (5.4%) cases gestational diabetes. Joint involvement represented the most frequent clinical manifestation of the cohort (57.9%), followed by RP (40.6%), photosensitivity (32.3%) and haematological manifestations (27.1%). The rate of disease evolution of our cohort from a diagnosis of UCTD to a diagnosis of definite CTD was 12% within a mean time of 5.3 ± 2.8 years. With a total follow-up after first pregnancy of 1417 patient-years, we observed the evolution to a defined CTD in one out of every 88 patient- years.

CONCLUSION: In our multicentre cohort, women with UCTD had a live birth rate of 79%. Women with UCTD should be referred to specialist follow-up when planning a pregnancy. ENA profiling and aPL testing should be mandatory in this setting, and further therapeutic approaches and management should be planned accordingly.

Original languageEnglish
JournalRheumatology (Oxford, England)
Volume59
Issue number9
Pages (from-to)2412-2418
Number of pages7
ISSN1462-0324
DOIs
Publication statusPublished - 1 Sep 2020

    Research areas

  • Abortion, Spontaneous/epidemiology, Adult, Antibodies, Antinuclear/blood, Antibodies, Antiphospholipid/blood, Autoantibodies/blood, Female, Fetal Growth Retardation/epidemiology, Humans, Live Birth/epidemiology, Pregnancy, Pregnancy Complications/blood, Pregnancy Outcome/epidemiology, Retrospective Studies, Stillbirth/epidemiology, Undifferentiated Connective Tissue Diseases/blood, anti-nuclear antibodies, pregnancy, undifferentiated connective tissue disease, autoimmune disease, neonatal lupus, congenital heart block, pregnancy complications, autoantibodies

ID: 61876054